Sun Pharma says 2018 sales may fall as U.S. market gets tougher | Reuters

By Zeba Siddiqui | MUMBAI MUMBAI India's largest drug group Sun Pharmaceutical Industries Ltd said on Friday its U.S. sales might fall this year because of pressure on drug prices, signalling tough market conditions in the United States for generic drugmakers.'The U.S. generics industry is facing rapidly changing market dynamics, (and) increased competitive intensity and customer consolidation is leading to pressure on pricing,' Sun's Managing Director Dilip Shanghvi said on a call with analysts after the company reported lower than expected fourth-quarter earnings.'We may even have a single digit decline in consolidated revenue for full-year 2018 versus full-year 2017.'The world's fifth-largest generic drugs maker is the latest to offer a bleak U.S

Reuters May 26, 2017 23:30:05 IST
Sun Pharma says 2018 sales may fall as U.S. market gets tougher
| Reuters

Sun Pharma says 2018 sales may fall as US market gets tougher
 Reuters

By Zeba Siddiqui
| MUMBAI

MUMBAI India's largest drug group Sun Pharmaceutical Industries Ltd said on Friday its U.S. sales might fall this year because of pressure on drug prices, signalling tough market conditions in the United States for generic drugmakers."The U.S. generics industry is facing rapidly changing market dynamics, (and) increased competitive intensity and customer consolidation is leading to pressure on pricing," Sun's Managing Director Dilip Shanghvi said on a call with analysts after the company reported lower than expected fourth-quarter earnings."We may even have a single digit decline in consolidated revenue for full-year 2018 versus full-year 2017."The world's fifth-largest generic drugs maker is the latest to offer a bleak U.S. forecast, echoing recent comments by rivals Dr Reddy's Laboratories Ltd and Lupin Ltd. India's nearly $16 billion drugs industry faces an uncertain future in its largest export market, the United States.

A wave of consolidation between U.S. drug distributors has hit the negotiating power of drugmakers. There is also uncertainty around big healthcare policy changes by U.S. President Donald Trump."For many things there is a new normal that is getting established," Sun's Shanghvi said in response to analysts queries on how the company planned to deal with the increasing challenges. "We are clearly at the level of profitability where we were 12 years back ... we need to execute better." Sun's plan, like that of other large Indian drugmakers, is to make niche products where there's less competition, such as for ophthalmology and dermatology.

Sun has been working on fixing problems at its western India-based Halol plant, where the U.S. Food and Drug Administration has raised concerns about quality control violations.Managing Director Shanghvi said the company was continuing to fix those issues as it awaited another inspection, which it had no visibility on.

It is also partnered with U.S. firm Merck & Co Inc on developing tildrakizumab, a new drug for psoriasis that Shanghvi said might be launched next year. Hit by a 34 percent fall in U.S. sales, Sun's profit for the quarter ended March fell 14 percent to 12.24 billion rupees ($189.94 million), lower than the 15 billion rupees that 21 analysts polled by Thomson Reuters expected, on average. Sales in its second-largest market, India, were up 10 percent, but the business will face a one-time hit from a nationwide tax reform that the government plants to implement July onwards, Shanghvi said.($1 = 64.4400 Indian rupees) (Reporting by Zeba Siddiqui in Mumbai. Editing by Jane Merriman)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Call with Biden was a return to traditional UK-U.S. relations, says UK's Johnson
World

Call with Biden was a return to traditional UK-U.S. relations, says UK's Johnson

LONDON (Reuters) - British Prime Minister Boris Johnson described his phone call with U.S. President-elect Joe Biden as a return to traditional issues in relations between Britain and the United States. "It was a kind of return to the kind of business that we're used to doing together: sticking up for democracy around the world, human rights, free trade, NATO, our joint security, the transatlantic alliance ..

Armenian PM's fate hangs in balance after Nagorno-Karabakh ceasefire
World

Armenian PM's fate hangs in balance after Nagorno-Karabakh ceasefire

By Nvard Hovhannisyan and Nailia Bagirova YEREVAN/BAKU (Reuters) - The fate of Armenia's prime minister hung in the balance on Wednesday after parliament agreed to discuss protesters' demands for his resignation over a ceasefire that secured territorial advances for Azerbaijan in Nagorno-Karabakh.